# A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Source: https://onco.cc/trials/nct06116136/  
OnCo record `nct06116136` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in gastric & gastro-oesophageal junction cancer, run by Servier Bio-Innovation LLC, active and no longer recruiting.

## Summary

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. is a phase 1/2 interventional study registered as NCT06116136 by Servier Bio-Innovation LLC, with 48 participants enrolled, started 2024-08-31 and due to reach its primary completion in 2027-08. Interventions recorded: S095029 and pembrolizumab 200 mg (KEYTRUDA ®).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06116136
- Phase: 1/2
- Setting: Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer
- Sponsor: Servier Bio-Innovation LLC
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT06116136: https://clinicaltrials.gov/study/NCT06116136

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06116136.json